Please wait a minute...
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2007, Vol. 8 Issue (2): 81-87    DOI: 10.1631/jzus.2007.B0081
Biotechnology     
Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation
WU Xiao-mo, FU Jing-geng, GE Wang-zhong, ZHU Jiang-yan, WANG Jun-yong, ZHANG Wei, QIAN Wei, HUO Ke-ke
Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objective: To establish a routine procedure for the detection of p53 mutations in hepatocellular carcinoma (HCC) surgical resections using the FASAY (functional analysis of separated alleles of p53 on yeast) procedure. Methods: p53 status was analyzed by FASAY and cDNA sequencing in 50 cases of HCC. After the extraction of RNA from the frozen tumor and corresponding normal tissues, reverse transcription RT-PCR was carried out using these samples. The assay can detect mutations of p53 mRNA between codons 67 and 347 by the DNA-binding activity of the protein and reveal them as red colonies. Results: Of the 50 specimens, 29 (58%) were positive (mutant) by FASAY. Sequencing analysis confirmed that all 29 FASAY positive tumors harbored mutations, and that no mutations were detectable in any FASAY negative tumors. In 29 p53 mutations, 22 mutations were point missense mutation, 5 were deletions and 2 were splicing mutations. A novel splice mutation on splice donor of intron 6 was reported, which could produce two different mRNAs, respectively using the nearest upstream and downstream recessive splice donor sites. Conclusion: FASAY is a sensitive method for detecting the various types of p53 mutations in HCC, suggesting that the yeast functional assay for the detection of p53 mutations may be essential for elucidating their clinical significance.

Key wordsHepatocellular carcinoma (HCC)      p53 mutation      FASAY      Splicing mutation     
Received: 20 September 2006     
CLC:  Q34  
Cite this article:

WU Xiao-mo, FU Jing-geng, GE Wang-zhong, ZHU Jiang-yan, WANG Jun-yong, ZHANG Wei, QIAN Wei, HUO Ke-ke. Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2007, 8(2): 81-87.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.2007.B0081     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2007/V8/I2/81

[1] Zhong-dong Wang, Fan-yong Qu, Yuan-yuan Chen, Zhang-shen Ran, Hai-yan Liu, Hai-dong Zhang. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 27-36.
[2] Yong-fang JIANG, Jing MA, Yan HE, Yong-hong ZHANG, Yun XU, Guo-zhong GONG. Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(1): 7-13.